OCA 25 mg demonstrated double the response rate of placebo in reduction of liver fibrosis without worsening of NASH; consistent antifibrotic effect shown across multiple analyses
OCA 25 mg showed increased antifibrotic efficacy in patients with advanced fibrosis without cirrhosis
Robust safety assessment of 2,477 patients, including 1,000 on study drug for four years, supports chronic administration of OCA
REGENERATE data to be presented in late-breaking oral session on Monday, November 7
Company remains on track to resubmit new drug application for OCA in liver fibrosis due to NASH by end of 2022
https://finance.yahoo.com/news/intercept-announces-additional-positive-data-130000354.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.